Recognizing resistance or susceptibility to the current standard cisplatin and paclitaxel treatment could improve therapeutic outcomes of metastatic or recurrent cervical cancer. | Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy